Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2020

ASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancer

ASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancer

ASCO 2020: Blood test predicts response to prostate cancer treatment

ASCO 2020: Blood test predicts response to prostate cancer treatment

ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumours

ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid...

ASCO 2020: Trastuzumab combined with trimodality treatment does not improve outcomes for patients

ASCO 2020: Trastuzumab combined with trimodality treatment does not improve outcomes for patients

ASCO 2020: Combined cediranib and olaparib presents similar activity to standard of care treatment

ASCO 2020: Combined cediranib and olaparib presents similar activity to standard of care treatment

ASCO 2020: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response

ASCO 2020: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows...

ASCO 2020: Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS

ASCO 2020: Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS

ASC0 2020: Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy

ASC0 2020: Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy

ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions

ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions

ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma

ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma

ASCO 2020: Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML

ASCO 2020: Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML

ASCO 2020: Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with specific DNA mutations

ASCO 2020: Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with...

ASCO 2020: Post-surgery osimertinib delays disease recurrence in patients with localised non-small cell lung cancer

ASCO 2020: Post-surgery osimertinib delays disease recurrence in patients with localised non-small cell lung cancer

ASCO 2020: Multinational consortium reports COVID-19 impact on cancer patients

ASCO 2020: Multinational consortium reports COVID-19 impact on cancer patients

ASCO 2020: Immunotherapy avelumab shows potential in rare gynaecological cancer resistant to chemotherapy

ASCO 2020: Immunotherapy avelumab shows potential in rare gynaecological cancer resistant to chemotherapy

ASCO 2020: Surgery and radiation do not extend survival in newly diagnosed metastatic breast cancer

ASCO 2020: Surgery and radiation do not extend survival in newly diagnosed metastatic breast cancer

ASCO 2020: Immunotherapy following chemotherapy offers extended survival to patients with advanced urothelial cancer

ASCO 2020: Immunotherapy following chemotherapy offers extended survival to patients with advanced urothelial...

ASCO 2020: Chemo within 3 months of COVID-19 diagnosis associated with an increased risk of death in patients with thoracic cancer

ASCO 2020: Chemo within 3 months of COVID-19 diagnosis associated with an increased risk of death in patients with...

ASCO 2020: Large scale precision medicine approach successfully applied to paediatric cancers with poor prognosis

ASCO 2020: Large scale precision medicine approach successfully applied to paediatric cancers with poor prognosis

ASCO 2020: Special report provides guidance to oncology practices on resuming cancer care during COVID-19 pandemic

ASCO 2020: Special report provides guidance to oncology practices on resuming cancer care during COVID-19 pandemic

ASCO 2020: Early data show cancer progression associated with increased risk of death in patients with COVID-19

ASCO 2020: Early data show cancer progression associated with increased risk of death in patients with COVID-19

ASCO 2020: Pembrolizumab plus chemotherapy demonstrated improvement in PFS for patients with metastatic triple-negative breast cancer

ASCO 2020: Pembrolizumab plus chemotherapy demonstrated improvement in PFS for patients with metastatic triple...

ASCO 2020: Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

ASCO 2020: Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over chemotherapy in metastatic first-line non-small cell lung cancer patients

ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over chemotherapy...

ASCO 2020: Apalutamide significantly improved overall survival in patients with non-metastatic castration-resistant prostate cancer

ASCO 2020: Apalutamide significantly improved overall survival in patients with non-metastatic castration...

ASCO 2020: Video conference intervention significantly reduces anxiety and distress among remote caregivers of people with cancer

ASCO 2020: Video conference intervention significantly reduces anxiety and distress among remote caregivers of...

ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation

ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with...

More from ecancer